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Conclusions. This study reveals a high degree of controversy over neoadjuvant HT in PC. HT is only accepted as part of the D’Amico
regimen.
http://dx.doi.org/10.1016/j.rpor.2013.03.479
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Resumen
Introduction and objectives. Cardiovascular mortality is the most important cause of death in prostate cancer (PC) patients. This
may partly relate to a greater risk ofmetabolic syndrome (MS) during long-term androgen deprivation therapy (ADT). The primary
objective of this analysis was to assess the prevalence of MS in men with PC before initiating ADT and after 12 months of ADT.
Materials and methods. ANAMET was an observational, prospective, multicentre, open study conducted in Spain to assess the
prevalence of MS in ADT-naïve PC patients during 12 months of treatment with quarterly gonadotropin-releasing hormone
(GnRH) agonists. MS was evaluated at baseline, 6 and 12 months after initiation of ADT. An increase of over 5% in MS prevalence
was considered clinically signiﬁcant.
Results.Of 535patients included in the study, 422 completed the study and310 completed all evaluations (per-protocol population).
In theper-protocol population,MSwasdetected in 71 (22.9%) patients at baseline and 83 (26.8%) after 12months ofADT (difference
of 3.9% and 95% CI [−0.3–8.1%]). Of the 71 patients with MS at baseline, 25 (35.2%) did not have MS after 12 months of ADT. Of
the 239 patients without MS at baseline, 37 (15.5%) had MS after 12 months of ADT.
Conclusion. Some increase in MS following 1 year of ADT with GnRH agonists was observed in this open observational study;
however, of the patients presenting with MS at baseline, there was a notable reduction in the number presenting with MS after 1
year of ADT. The prevalence of MS was high at baseline in this ADT-naïve population, suggesting that other measures unrelated
to PC therapy (such as weight control) are important for reducing the risk of MS in this population. More long-term observational
data are needed to elucidate the impact of ADT on MS.
http://dx.doi.org/10.1016/j.rpor.2013.03.480
Dose-escalated salvage radiotherapy increase biochemical control in localized prostate cancer
J. Rodríguez Melcón1, L. Henríquez Hernández2, M. Federico1, L. García Cabrera1, B. Pinar Seden˜o1,
P. Lara Jiménez1
1 Hospital Universitario de Gran Canaria Dr. Negrín, Oncología Radioterápica, Spain
2 Hospital Universitario de Gran Canaria Dr. Negrín, Oncología Radioterápica, Unidad de Investigación, Spain
Purpose/objective. To retrospectively evaluate the outcomes and prognostic factors of salvage External Beam Radiotherapy (EBRT)
after Radical Prostatectomy (RP) for localized prostate cancer (PCa) with different dosing schedules.
Material/methods. Data from 159 patients referred from 4 different urology departments between 2007 and 2012, were included
in a retrospective study describing referral criteria for postoperative EBRT. From that series, 20 were referred for adjuvant-
EBRT, 9 did not receive EBRT and 8 had not a post-RP PSA. Finally 122 consecutive patients, referred for salvage-EBRT were
included in the present study. Clinical and pathological data were analyzed, including pT stage, Gleason score, margin status,
perineural invasion, pre-EBRT PSA, and EBRT dose. Clinical outcome was evaluated as Biochemical Progression-Free Survival
(BPFS). Pathological ﬁndings showed a 58.2% of pT3a-b/T4 tumours and 59% of positive margins. An undetectable level of post-RP
PSA (<0.10ng/ml) was reached by 46.7%, while a permanently detectable-PSA (PD-PSA, ≥0.10ng/ml) was present in 53.3%. The
limit of a pre-EBRT PSA ≥1ng/ml was exceeded in 41% of patients. The delivered EBRT doses were: 66Gy (17.2%), 70Gy (55.7%)
and 72–74Gy (27.1%).
Results. The median follow-up was 17 months. The probability of BPFS at 3 years was 72.4%. No differences were found in terms
of patient referral as relapsed or PD-PSA. Doses ≥72Gy were associated to increased BPFS at 3 years (89% vs. 59%; p=0.044)
compared to lower doses (66–70Gy). Higher doses were related to increased BPFS in patients meeting adjuvant-EBRT criteria
(pT3a-b/T4 or positive margins; p=0.026 and 0.002, respectively). Furthermore, patients with pre-EBRT PSA levels <1ng/ml has a
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strong trend toward better BPFS (p=0.079). In multivariate analysis only EBRT dose was signiﬁcant for BPFS (p=0.035; Exp(B):15.24;
95%CI:1.21–191).
Conclusions. Dose escalation ≥72Gy was associated with increased BPFS rates. Higher EBRT doses mainly beneﬁt patients referred
to salvage-EBRT but who previously met adjuvant-EBRT criteria.
http://dx.doi.org/10.1016/j.rpor.2013.03.481
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Evaluation of local disease extend is typically accomplished with the combination of digital rectal examination (DRE) and tran-
srectal ultrasound at the time of biopsy. Magnetic resonance imaging (MRI) is widely available in our department, and therefore
we usually apply it in the initial evaluation of men with newly diagnosed prostate cancer. The aim of this descriptive study is to
evaluate all prostate cancer patients who were undergone external radical external beam radiotherapy (EBRT) in our department
and to know how many of them have a MRI. Likewise, to determine if there is a therapeutic change in the initial strategy. Between
January 2009 and November 2012 were included 198 patients with newly diagnosed prostate who received EBRT. Patients with
a previous prostatectomy and palliative patients were excluded. Age average 69 years old (50–83), originally we arrange by risk
of recurrence according DRE, PSA and Gleason, we obtained 27.8% Low Risk, 41.4% Intermediate Risk and 30.8% High Risk. 80%
of whole of them received androgen deprivation therapy (ADT), so 10% received ADT without selection criteria by urologist. 114
patients (57%) had a MRI, 31 of them there was a therapeutic change, almost in 30% of the patients with MRI. Of them, 10 patients
could be changed at total length of ADT or planning tumor volumes (PTV) and 21 patients this therapeutic change consisted
of both, planning tumor volumes (PTV) and total length of ADT. 57 patients were found with a different clinical stage. In our
experience MRI is additional tool to staging prostate cancer, overall we think is useful to determine extracapsular invasion, when
Gleason ≥8 or Gleason 7 (4 + 3), besides of that cases which DRE do not provide a clear information.
http://dx.doi.org/10.1016/j.rpor.2013.03.482
Feasibility of PET-CT 18F-ﬂuorocholine to increase doses in intraprostatic lesions in radiation treatments for
prostate cancer
J. Pastor Peidro1, T. García Hernández2, A. Vicedo González2, J. López Torrecilla1, J. Roselló Ferrando2,
J. Ferrer Rebolleda3, P. Almendros Blanco1, L. Brualla González2, A. Hernández Machancoses1,
D. Granero Caban˜ero2
1 Hospital General Universitario, Oncología Radioterápica-ERESA, Spain
2 Hospital General Universitario, Radiofísica-ERESA, Spain
3 Hospital General Universitario, Medicina Nuclear-ERESA, Spain
Introduction. Dose escalation in prostate cancer treatment has shown an improvement in local and biochemical control. However,
this carries a risk of increasing toxicity. A reduction in the irradiated volume,with a boost on intraprostatic lesions (IL), determined
by 18F-choline PET/CT facilitate the optimization of the dose to organs at risk (OR).
Objective. To study the feasibility of dose escalation >80Gy in IL, deﬁned by 18F-choline PET/CT, analyzing the dose variation to
organs at risk (OR) in relation to traditional CT planning.
Materials and methods. In 10 patients with prostate cancer, we performed a dynamic PET and a second conventional PET 30min
after injection of 5–7mCi of 18F-choline in a PET/CT-Gemini-TF-Philips. The IL were deﬁned using a ratio of intraprostatic prob-
able lesion “Standardized uptake value” (SUV)/background prostate gland SUV>2. We generated two treatment plans with and
without boost to IL. We compared the dose to 15, 25, 35 and 50% (D15, D25, D35 and D50) of rectal volume in both plans and with
protocol constraints of our service
Results. The rectal dose variation between treatments with and without boost depends on the location of the IL and the relation-
ship between the volume of IL and the whole prostate. Using metabolic information of PET-CT in each patient, the mean increase
in rectal dose was D15:1.4%, D25:1.2%, D35:1% and D50:1.5%. For a distance from IL to the rectum >8mm, the dose increase to
the rectum was negligible. The rectal dose was kept below the constraints of our protocols.
Conclusions. Dose escalation in the IL, deﬁned by 18F-choline PET/CT, represents a slight increase in rectal dose remaining in all
cases within the constrains.
http://dx.doi.org/10.1016/j.rpor.2013.03.483
